These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Unprecedented response to combination BRAF and MEK inhibitors in adult anaplastic ganglioglioma. Beland B; Tsang RY; Sutherland G J Neurooncol; 2018 May; 137(3):667-669. PubMed ID: 29335912 [No Abstract] [Full Text] [Related]
5. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673 [TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of BRAF status in glial and glioneuronal tumors: A systematic review. Sugiura Y; Nagaishi M J Clin Neurosci; 2019 Aug; 66():196-201. PubMed ID: 31147232 [TBL] [Abstract][Full Text] [Related]
7. Role of diffusion weighted imaging for differentiating cerebral pilocytic astrocytoma and ganglioglioma BRAF V600E-mutant from wild type. Ramaglia A; Tortora D; Mankad K; Lequin M; Severino M; D'Arco F; Löbel U; Benenati M; de Leng WWJ; De Marco P; Milanaccio C; Rossi A; Morana G Neuroradiology; 2020 Jan; 62(1):71-80. PubMed ID: 31667545 [TBL] [Abstract][Full Text] [Related]
8. Rare Activating BRAF Alteration Involving the β3-αC Kinase Domain in Ganglioglioma. Lin CC; Lefferts JA; Chan AM; Zanazzi G J Neuropathol Exp Neurol; 2021 Sep; 80(9):887-889. PubMed ID: 33611593 [No Abstract] [Full Text] [Related]
9. The genetic landscape of ganglioglioma. Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043 [TBL] [Abstract][Full Text] [Related]
10. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608 [TBL] [Abstract][Full Text] [Related]
11. BRAF somatic mutation contributes to intrinsic epileptogenicity in pediatric brain tumors. Koh HY; Kim SH; Jang J; Kim H; Han S; Lim JS; Son G; Choi J; Park BO; Heo WD; Han J; Lee HJ; Lee D; Kang HC; Shong M; Paik SB; Kim DS; Lee JH Nat Med; 2018 Nov; 24(11):1662-1668. PubMed ID: 30224756 [TBL] [Abstract][Full Text] [Related]
12. Transformation of ganglioglioma to epithelioid glioblastoma, both with BRAF V600E mutation. Lau S; Clark J; Lokan J Pathology; 2022 Aug; 54(5):645-647. PubMed ID: 34895740 [No Abstract] [Full Text] [Related]
14. BRAF V600E-Mutated Ganglioglioma of the Optic Pathway: A Case Report and Review of the Literature. Solomon AM; Chia TMT; Juric-Sekhar G; Francis CE J Neuroophthalmol; 2021 Dec; 41(4):e723-e727. PubMed ID: 33394641 [No Abstract] [Full Text] [Related]
15. Analysis of KIAA1549-BRAF fusion status in a case of rosette-forming glioneuronal tumor of the fourth ventricle (RGNT). Gessi M; Waha A; Setty P; Waha A; Pietsch T Neuropathology; 2011 Dec; 31(6):654-7. PubMed ID: 21518014 [TBL] [Abstract][Full Text] [Related]
16. Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Bourque MS; Salek M; Sabin ND; Canale M; Upadhyaya SA Pediatr Blood Cancer; 2021 Apr; 68(4):e28814. PubMed ID: 33211390 [No Abstract] [Full Text] [Related]
17. Epilepsy Outcome and Pathology Analysis for Ganglioglioma: A Series of 51 Pediatric Patients. Liu Q; Cai L; Sun Y; Wang Y; Yu H; Liu C; Wang H; Zhang S; Gong J Pediatr Neurol; 2023 Dec; 149():127-133. PubMed ID: 37879136 [TBL] [Abstract][Full Text] [Related]
18. Recurrent ganglioglioma in adults treated with BRAF inhibitors. Chamberlain MC CNS Oncol; 2016; 5(1):27-9. PubMed ID: 26680369 [TBL] [Abstract][Full Text] [Related]